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ABSTRACT
Objectives: To predict the anticancer potentiality of some newly designed azaindole derivatives gainst human Aurora B kinase and to identify the 
critical features important for their activity.
Methods: Initially, the derivatives of azaindoles, (Z)-2-(oxo-1 H-pyrrolo [2,3-b] pyridine-3 (2H)-ylidene)-N-(p-substituted) hydrazine carbothioamide 
(scaffold A), (E)-3-((E)-substituted benzylidene hydrazono)-1H-pyrrolo[2,3-b]pyridine-2(3H)-one (scaffold B), and 1-(2-substituted acetyl)-1H-
pyrrolo [2,3-b]pyridine-2,3-dione are synthesized and sketched using ACD/ChemSketch (12.0). With the 3D converted compounds, docking into the 
active site of the retrieved protein Aurora B kinase is carried out using LibDock module of discovery studio (DS). Further absorption, distribution, 
metabolism, excretion and toxicity (ADMET) properties, ligand, and structure-based pharmacophore modeling are applied using DS.
Results: Through docking and pharmacophore studies, it is revealed that compound C13 (N-{(Z)-2-[4-(dimethylamino)phenyl]ethenyl}-1H-
pyrrolo[2,3-b]pyridine-3-carboxamide) shows the highest binding affinity and good pharmacophoric features with acceptable fit values of both ligand 
and structure-based pharmacophore models. Furthermore, the calculated ADMET properties are reliable.
Conclusion: These studies suggest that the compound C13 (N-{(Z)-2-[4-(dimethylamino)phenyl]ethenyl}-1H-pyrrolo[2,3-b]pyridine-3-carboxamide) 
may act as a potent target in the anticancer therapy.
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INTRODUCTION
Aurora kinases with their interference in various aspects of underlying 
cell cycle mitotic events, over expressions in malignancy and 
interference with tumor suppressor and oncogenic signaling pathways, 
they have arised as encouraging chemotherapeutic targets for cancer 
and many diseases accompanied by their deregulation [1-3]. Aurora’s 
are a family of well homologous serine-threonine protein kinases that 
play an important role in controlling a series of activities at different 
stages from G2 to cytokinesis during cell division through which normal 
cell cycle mitosis is maintained [4-6]. The mitotic regulation is necessary 
for equal and accurate chromosomal segregation to daughter cells 
during cell division and is of great consequence to preserve genome 
stability and prevent aneuploidy [7-9]. Hence, any perturbations of the 
Aurora kinases disorganize mitotic processes leading to chromosomal 
instability and aneuploidy that is commonly observed in many human 
cancer cells, which is evident by chromosome loss, translocation 
and aberrant centrosome duplication, indicating an underlying 
deregulation in chromosome segregation, centrosome duplication and 
segregation [8-10]. In particular, this critical activity of Aurora kinases 
put forward that their blockage may result in arrest of the cell cycle in 
cancer cells that have been of intense research in identifying distinctive 
Aurora kinase inhibitors as probable lead molecules for cancer [11,12].
Aurora B kinase is a member of Aurora family, found as a catalytic part 
of the four-subunit chromosomal passenger complex (CPC) along with 
INCENP, Survivin and Borealin which are codependent for stability and 
localization [13-15]. These proteins share a characteristic pattern of 
association with chromatin in prophase, centromeres in metaphase and 
early anaphase, and then the midzone and midbody in late anaphase 
and telophase, respectively [16-18]. This differential localization of 
the CPC throughout mitosis suggested that this complex ensures the 
effective and spatially restricted phosphorylation of substrates involved 
in chromosome condensation, correction of erroneous kinetochore-
microtubule attachments, activation of the spindle assembly checkpoint 
(SAC), and constructs contractile apparatus during cytokinesis. Given 
the critical and diverse roles of Aurora B in mitosis and cytokinesis, 
its cellular functions require proper regulation by inducing 
autophosphorylation through several mechanisms and controlled 
interactions with its substrates. Knockdown of any member of the 
complex delocalizes the others where Aurora B activity is diminished 
disrupts mitotic progression that might correlate with aneuploidy 
which continues to the formation of an abnormal nuclear morphology 
in cancer cells [19-24]. Therefore, modulations of these altered 
mechanisms through the inhibition of Aurora B kinase is considered as 
a therapeutic strategy in many cancers where it contribute its role in 
proper cell cycle events leading to mitotic progression associated with 
genome stability.
In this study, we have investigated the anticancer activity of synthetic 
derivatives of azaindole against Aurora B kinase through docking, 
pharmacophore and absorption, distribution, metabolism, excretion 
and toxicity (ADMET) studies. The overall results obtained from this 
study reveal that these compounds would aid in designing new lead 
molecules in cancer therapy.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i2.14974
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Chemistry
A series of azaindole derivatives, (Z)-2-(oxo-1 H-pyrrolo [2,3-b] 
pyridine-3 (2H)-ylidene)-N-(p-substituted) hydrazine carbothioamide 
(scaffold A), (E)-3-((E)-substituted benzylidene hydraz--ono)-1H-
pyrrolo[2,3-b]pyridine-2(3H)-one (scaffold B), and 1-(2-substituted 
acetyl)-1H-pyrrolo [2,3-b]pyridine-2,3-dione are synthesized 
schematically. The synthetic pathway for the synthesis of our targeted 
compounds is illustrated in Scheme 1. Fig. 1 shows the chemical 
structures of the scaffolds. The derivatives of the scaffolds with different 
substitutions in the R position, their IUPAC names, molecular formula 
and molecular weight are tabulated in Table 1.
METHODS
Protein preparation
The structure of human Aurora B Kinase (PDB: 4AF3) complexed 
with VX-680 and INCENP is retrieved from the PDB database having 
a resolution of 2.75 Å. After importing into the discovery studio 
2.5 (DS), using the clean Protein protocol, the protein is prepared for 
correcting the lack of hydrogen atoms, missing atoms and residues, 
incorrect atom order in amino acids, protonation states of ionizable 
side chains and terminal groups using predicted pKs, to complete 
the protein chain. Water molecules and all the heteroatoms are 
removed, and CHARMm force field is applied for energy minimization 
using different algorithms till the protein reaches a convergence 
Scheme 1: Synthetic pathway for azaindole derivatives
Fig. 1: Chemical structure of the scaffolds a-c
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Table 1: Molecular properties of the azaindole derivatives





A1 H C14H11N5OS 297.33504 (2Z)-2-(2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b] 
pyridin-3-ylidene)-N-phenylhydrazine carbothioamide
A2 Cl C14H10ClN5OS 331.7801 (2Z)-N-(4-chlorophenyl)-2-(2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b] 
pyridin-3-ylidene) hydrazine carbothioamide
A3 F C14H10FN5OS 315.3255032 (2Z)-N-(4-fluorophenyl)-2-(2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b] 
pyridin-3-ylidene) hydrazine carbothioamide
A4 OH C14H11N5O2S 313.33444 (2Z)-N-(4-hydroxyphenyl)-2-(2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b] 
pyridin-3-ylidene) hydrazine carbothioamide
A5 Br C14H10BrN5OS 376.2311 (2Z)-N-(4-bromophenyl)-2-(2-oxo-1,2-dihydro-3H-pyrrolo[2,3-b] 
pyridin-3-ylidene) hydrazine carbothioamide
B1 CH3 C15H12N4O 264.28198 (3Z)-3-[(2E)-(4-methylbenzylidene) hydrazineylide 
ne]-1,3-dihydro-2H-pyrrolo[2,3-b] pyridin-2-one
B2 H C14H10N4O 250.2554 (3Z)-3-[(2E)-benzylidenehydrazinylidene]-1,3-dihydro-2H-pyrrolo[2,3-b] 
pyridin-2-one
B3 Cl C14H9ClN4O 284.70046 (3Z)-3-[(2E)-(4-chlorobenzylidene) 
hydrazinylidene]-1,3-dihydro-2H-pyrrolo[2,3-b] pyridin-2-one
B4 F C14H9FN4O 268.2458632 (3Z)-3-[(2E)-(4-fluorobenzylidene) 
hydrazinylidene]-1,3-dihydro-2H-pyrrolo[2,3-b] pyridin-2-one
B5 NH2 C14H11N5O 265.27004 (3Z)-3-[(2E)-(4-aminobenzylidene) 
hydrazinylidene]-1,3-dihydro-2H-pyrrolo[2,3-b] pyridin-2-one
B6 OH C14H10N4O2 266.2548 (3Z)-3-[(2E)-(4-hydroxybenzylidene) 
hydrazinylidene]-1,3-dihydro-2H-pyrrolo[2,3-b] pyridin-2-one
B7 N (CH3)2 C16H15N5O 293.3232 (3Z)-3-{(2E)-[4-(dimethylamino) benzylidene] 
hydrazinylidene}-1,3-dihydro-2H-pyrrolo[2,3-b] pyridin-2-one
B8 OCH3 C15H12N4O2 280.28138 (3Z)-3-[(2E)-(4-methoxybenzylidene) 
hydrazinylidene]-1,3-dihydro-2H-pyrrolo[2,3-b] pyridin-2-one
B9 C16H12N4O 276.29268 (3Z)-3-{(2E)-[(2E)-3-phenylprop-2-en-1-ylidene] 
hydrazinylidene}-1,3-dihydro-2H-pyrrolo[2,3-b] pyridin-2-one
C1 HN-C6H5 C15H11N3O3 281.26614 1-[(phenylamino) acetyl]-1H-pyrrolo[2,3-b] pyridine-2,3-dione
C2 HN-C6H4Cl C15H10ClN3O3 315.7112 1-{[(4-chlorophenyl) amino] acetyl}-1H-pyrrolo [2,3-b] pyridine-2,3-dione
C3 HN-C6H4F C15H10FN3O3 299.2566032 1-{[(4-fluorophenyl) amino] acetyl}-1H-pyrrolo [2,3-b] pyridine-2,3-dione
C4 HN-C6H4Br C15H10BrN3O3 360.1622 1-{[(4-bromophenyl) amino] acetyl}-1H-pyrrolo [2,3-b] pyridine-2,3-dione
C5 HN-C6H4CH3 C16H13N3O3 295.29272 1-{[(4-methylphenyl) amino] acetyl}-1H-pyrrolo [2,3-b] pyridine-2,3-dione
C6 HN-C6H4OCH3 C16H13N3O4 311.29212 1-{[(4-methoxyphenyl) amino] acetyl}-1H-pyrrolo [2,3-b] pyridine-2,3-dione
C7 HN-C6H4CH3 C16H13N3O3 295.29272 1-{[(2-methylphenyl) amino] acetyl}-1H-pyrrolo [2,3-b] pyridine-2,3-dione
C8 HN-C6H4Cl C15H10N3O3 315.7112 1-{[(2-chlorophenyl) amino] acetyl}-1H-pyrrolo [2,3-b] pyridine-2,3-dione
C9 HN-C6H4F C15H10FN3O3 299.2566032 1-{[(2-fluorophenyl) amino] acetyl}-1H-pyrrolo [2,3-b] pyridine-2,3-dione
C10 HN-C6H4Br C15H10BrN3O3 360.1622 1-{[(2-bromophenyl) amino] acetyl}-1H-pyrrolo [2,3-b] pyridine-2,3-dione
C11 HN-C6H4OCH3 C16H13N3O4 311.29212 1-{[(2-methoxyphenyl) amino] acetyl}-1H-pyrrolo[2,3-b] pyridine-2,3-dione
C12 HNC (HN₂)₂ C10H9N5O3 247.21016 1-[2-(2,3-dioxo-2,3-dihydro-1H-pyrrolo[2,3-b] pyridin-1-yl)-2-oxoethyl] 
guanidine
C13 HNSO2C6H4-NH2 C15H12N4O5S 360.34458 4-amino-N-[2-(2,3-dioxo-2,3-dihydro-1H-pyrrolo[2,3-b] 
pyridin-1-yl)-2-oxoethyl] benzene sulfonamide
gradient 0.001 kcal/mol. Fig. 2 shows the human Aurora B Kinase 
crystal structure.
Ligand generation and optimization
Using ACD/ChemSketch (12.0), the 2D structures of all the compounds 
are drawn and saved in mol file format. These saved compounds 
are later imported into DS and ligand preparation with constraint 
parameters such as consistency of ionization states, tautomer and 
isomer generation, removal of duplicate structures, conversion of 
2D to 3D structures using catalyst algorithm is done and are energy 
minimized until the convergence gradient of 0.001 kcal/mol is reached. 
Fig. 3 shows the 3D structure of the compounds.
Define binding site
Using define and edit binding site tools in DS, the binding site of the 
human Aurora B Kinase is determined based on the occupied volume of 
the known ligand VX-680 in the active site. The ligand is first selected, 
and a sphere is created around the residues comprising binding site at a 
radius of 9 Å using define sphere from the selection option.
Docking studies
For accurate docking of our compounds into active site of the protein, 
molecular docking is carried out through site-featured docking 
algorithm Libdock module in DS. The binding site features, “HotSpots” 
are resolved with a grid fixed in active site which counts the hotspot 
map for polar and a polar cluster and further used for the alignment 
of the ligand conformations to the protein interaction sites. Finally, it 
returns all the minimized ligand poses and based on the high LibDock 
score; each pose is assessed for estimating binding energies and the 
protein-complex pose with the best binding energy is used for further 
binding mode analysis.
Pharmacophore model generation and validation
Two different methods are applied for the pharmacophore model 
generation using DS Catalyst: Ligand (common feature approach) and 
structure-based pharmacophore modeling, to analyze the fitting of the 
designed compounds to the generated pharmacophores.
Ligand-based pharmacophore modeling
Using HipHop algorithm in DS, Common feature pharmacophore 
modeling is applied with synthesized inhibitors of our target protein 
Aurora B kinase, which takes advantage of the chemical features 
commonly observed in the active compounds for the pharmacophore 
generation. Using DS diverse conformation generation module, a 
maximum of 255 conformations are created per compound using FAST 
Conformer method within an energy range 20 kcal/mol over the global 
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energy minimum. All the possible pharmacophore feature mappings 
with desired chemical groups are identified with Feature Mapping 
module and common feature pharmacophore generation protocol 
is executed including the features like, hydrogen bond donor (HBD), 
hydrogen bond acceptor (HBA), hydrophobic (HY), ring aromatic (RA), 
and positive ionizable (P) with principal value as “2,” maximum omit 
feature value as “0” and minimum inter-feature distance as “2.97 Å.” 10 
pharmacophore hypotheses are generated preferring the best one with 
high ranking score which further analyzed for compound mapping. The 
best-mapped compound is chosen based on the fit values and aligned 
pharmacophoric features.
Structure-based pharmacophore modeling
To further identify the critical structural features of our target 
protein Aurora B kinase, structure-based pharmacophore modeling 
is employed utilizing the current knowledge of the protein - ligand 
interactions. To construct a pharmacophore model, corresponding 
possible interaction points from the protein’s active site is computed 
using DS ‘Interaction Generation’ protocol. The active site is 
then analyzed for HBD, acceptors, and HY features by generating 
pharmacophore query from the Ludi interaction maps. The maximum 
Fig. 2: The structure of human Aurora B Kinase (PDB ID:4AF3) 
complexed with VX-680
Fig. 3: 3D structures of the compounds
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and minimum features are set to 2 and 1, respectively. The selected 
features are then clustered using edit and cluster pharmacophores 
tool, and a structure-based pharmacophore model is generated 
which further validated according to the compounds orientation 
in the active site using DS ligand pharmacophore mapping protocol 
with best flexible search option and maximum omitted features as 2. 
The predictive ability of the model was analyzed based on the best-
fit values that signify how well the compounds are fitted onto the 
pharmacophoric features.
ADMET studies
ADMET analysis is performed using DS ADMET descriptors protocol 
to derive the drug likeliness properties of the synthesized compounds 
which include absorption, blood–brain barrier (BBB), aqueous solubility, 
hepatotoxicity, plasma protein binding (PPB), and cytochrome P450 
(CYP) 2D6_probability enzyme inhibition study. Results are analyzed 
according to the DS standard parameters.
RESULTS AND DISCUSSION
Docking studies
Docking studies carried out using LibDock is used to analyze binding 
modes and affinities of the compounds with human Aurora B kinase 
(PDB:4AF3). Of all the conformations generated for each compound, 
the compound with the highest LibDock score is taken for interaction 
analysis of the hydrogen bonding. LibDock scores of all the compounds 
along with their hydrogen bond interactions and bond lengths are 
depicted in Table 2. From the overall docking and interaction analysis, 
the best conformation of the compound C13 docked complex shows 
high LibDock score of 116.558 kcal/mol and forms three hydrogen 
bonds with the protein Aurora B kinase (Fig. 4).
Pharmacophore modeling and validation
Ligand-based pharmacophore modeling
The HipHop algorithm computes ten common pharmacophore 
hypotheses with their ranking scores ranging from 266.453 to 249.195 
(Table 3), and hypothesis 1 is considered as the most reliable 
pharmacophore hypothesis (Fig. 5a) containing three HBD and one RA 
feature. All the compounds are mapped on to the hypothesis 1, ranked 
according to their fit values (Table 4) and the compound C13 fitted well 
on the pharmacophore with a high fit value of 4.093 (Fig. 5b).
Structure-based pharmacophore modeling
The Interaction Generation protocol constructed a structured-
based pharmacophore model of our protein human Aurora B Kinase 
based on the active site residues inside the sphere. The final edited 
pharmacophore model has two HBD, two HBA, and two HY features 
(Fig. 6a). Using ligand pharmacophore mapping, compounds are 
mapped and ranked according to the fit values (Table 5). Based on the 
fit values, the compound C13 fitted well on the pharmacophore with a 
fit value of 3.159 (Fig. 6b).
ADMET studies
The compounds are further examined by their pharmacokinetic and 
toxicity studies using ADMET descriptors analysis protocol in DS. Using 
the standards provided by DS, the results are analyzed. The calculated 
parameters are tabulated in Table 6. According to the DS parameters, 
Table 2: Summary of docking information of the top ranked poses of the compounds (A-1 to A-5 , B-1 to B-9 and C1-C13) with Human 
Aurora B Kinase (PDB ID: 4AF3)
Name Electrostatic 
energy
Van der waals 
energy
LibDock score Interacting 
aminoacids
Interacting atoms h-bond distance












A2:H26 - A: LEU83:O
A2:H26 - A: LEU83:C
A2:H30 - A: LYS106:CD
A2:H30 - A: LYS106:HD1












A3:H26 - A: LEU83:O
A3:H26 - A: LEU83:C
A3:H29 - A: LYS106:CD











A4:H26 - A: LEU83:O 2.304000






A5:H26 - A: LEU83:O
A5:C17 - A: LYS106:HZ2
A5:H29 - A: LYS106:CD









No ligand interaction atoms
(Contd...)
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Van der waals 
energy
LibDock score Interacting 
aminoacids
Interacting atoms h-bond distance




No ligand interaction atoms




No ligand interaction atoms





B4:H28 - A: LYS106:CD
B4:H28 - A: LYS106:HD2









B5:H24 - A: LEU83:O
B5:H24 - A: LEU83:C
B5:H29 - A: LYS106:HZ2
B5:H25 - A: LEU207:HD21












B6:H24 - A: LEU83:O
B6:H24 - A: LEU83:C
B6:H29 - A: LYS106:HZ2
B6:H25 - A: LEU207:HD21












B7:C17 - A: ALA217:HB1
B7:C18 - A: LYS106:HZ2
B7:H27 - A: LEU207:HD21











B8:H25 - A: LEU83:O
B8:H25 - A: LEU83:C
B8:H26 - A: LEU207:HD21











B9:H25 - A: LEU83:O
B9:H26 - A: LEU207:HD11










C1:O14 - A: LEU207:HD21 1.783000






No Ligand interaction atoms





No Ligand interaction atoms






No Ligand interaction atoms
(Contd...)
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Name Electrostatic 
energy
Van der waals 
energy
LibDock score Interacting 
aminoacids
Interacting atoms h-bond distance






No ligand interaction atoms






C6:H28 - A: LEU207:HD11
A: GLU161:HN - C6:O10
1.492000
2.483000






C7:H26 - A: LEU207:HD11
C7:O14 - A: LEU207:HD21
1.713000
1.824000






C8:C18 - A: GLY160:HA1
C8:H30 - A: TYR156:CE1
2.205000
1.866000






C9:O14 - A: LEU207:HD21
C9:H26 - A: LEU207:HD11
1.820000
1.776000






C10:H30 - A: TYR156:CE1
C10:H30 - A: TYR156:HE1










A: ALA157:HN - C11:O10
A: LYS106:HZ2 - C11:O22
C11:H29 - A: LYS106:HZ2
C11:H32- A: LEU207:HD21












A: LYS106:HZ2 - C12:O10
C12:N4 - A: LEU207:HD21
2.372000
1.825000






A: ALA157:HN - C13:O10
A: LYS106:HZ2 - C13:N15
A: LYS106:HZ1 - C13:O18
C13:H35- A: LEU207:HD21
C13:C23- A: LEU207:HD21
C13:H31 - A: LYS106:NZ









standard analysis value like level 0 for human intestinal absorption, 
level 3 and level 4 for solubility, level 0 for non-inhibitory property 
with CYP450 2D6, level 3 for BBB penetration, and level 0 for non-
toxicity were filtered for obtaining drug like compounds. Fig. 7 shows 
the plot of predicted values of drug absorption for our compounds. 
X-axis indicates the solubility of the compounds and Y-axis indicates 
the log p values. ADMET descriptors, the 2D polar surface area_2D in 
A2 per compound is plotted against their consonant estimated atom-
type partition coefficient (ALogP98). The space covered by the ellipse 
is a prophecy of excellent absorption without any violation of ADMET 
properties.
Ellipses indicate the absorption model at 95% and 99% confidence 
limit to the BBB and intestinal absorption models.
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Fig. 4: Hydrogen bond interactions of compound C13 with human 
Aurora B Kinase
Fig. 7: Plot of polar surface area versus LogP for candidate 
compounds showing the 95% and 99% confidence limit 
ellipses corresponding to the blood-brain barrier and intestinal 
absorption models
Table 3: Features shared by the 10 hypotheses in the common 
feature pharmacophore model
Hypothesis Feature Rank MaxFit
01 RAAA 266.453 4
02 RAAA 263.238 4
03 RAAA 262.038 4
04 RAAA 257.714 4
05 RAAA 256.747 4
06 RAAA 255.740 4
07 RAAA 252.218 4
08 RAAA 251.802 4
09 RAAA 250.133 4
10 HAAA 249.195 4
CONCLUSION
In this study, the synthesized azaindole derivatives are examined for 
their anticancer activity against the targeted protein Aurora B kinase 
through docking studies. The docking results analyzed the important 
and specific interactions, which are important for describing the affinity 
of these ligand molecules toward the protein. In addition, the conducted 
pharmacophore studies revealed the critical chemical features of the 
ligand and structural features of the protein responsible for their 
protein-ligand complex binding. Furthermore, the ADMET properties 
Table 4: Predicted fit values of compounds from the common 
feature-based hypothesis hypothesis 1




























Fig. 5: (a) Generated common feature-based ligand 
pharmacophore model (hypothesis 1) showing the hydrogen 
bond acceptors (green) and the ring aromatic feature (orange), 
(b) alignment of the compound C13 on the common feature 
pharmacophore model
a b
Fig. 6: (a) structure-based pharmacophore model of human 
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Table 5: The predicted fit values of compounds from the structure-based pharmacophore model of human aurora B kinase
Name Acceptor 13 Acceptor 9 Donor 28 Donor 49 Fit value Hydrophobe 10 Hydrophobe 24 Pharmprint
C13 1 0 1 1 3.159 1 0 ‘011110’
C6 1 1 0 0 2.721 1 1 ‘110011’
C11 0 1 1 0 2.661 1 1 ‘101011’
C8 0 1 1 0 2.405 1 1 ‘101011’
C9 0 1 1 0 2.285 1 1 ‘101011’
A4 1 0 1 0 2.22 1 1 ‘011011’
C10 0 1 1 0 2.178 1 1 ‘101011’
C7 0 1 1 0 2.139 1 1 ‘101011’
B6 1 1 0 0 2.029 1 1 ‘110011’
C5 1 0 1 0 1.981 1 1 ‘011011’
B8 1 1 0 0 1.882 1 1 ‘110011’
C2 1 0 1 0 1.878 1 1 ‘011011’
C3 0 1 1 0 1.873 1 1 ‘101011’
C4 0 1 1 0 1.842 1 1 ‘101011’
C1 0 1 1 0 1.813 1 1 ‘101011’
A2 1 0 1 0 0.843 1 1 ‘011011’
A5 1 0 1 0 0.795 1 1 ‘011011’
A1 1 0 1 0 0.758 1 1 ‘011011’
A3 1 0 1 0 0.736 1 1 ‘011011’
C12 1 0 1 1 0.325 1 0 ‘011110’
B5 0 0 1 1 0.146 1 1 ‘001111’
Table 6: Predicted ADMET properties of the compounds
Name BBB Absorption Solubility Hepatotoxicity CYP2D6 PPB
A1 3 0 3 1 0 2
A2 3 0 2 1 0 2
A3 3 0 3 1 0 2
A4 3 0 3 1 0 2
A5 3 0 2 1 0 2
B1 2 0 3 1 0 2
B2 3 0 3 1 0 2
B3 2 0 2 1 0 2
B4 2 0 3 1 0 2
B5 3 0 3 1 0 2
B6 3 0 3 1 0 2
B7 3 0 3 1 0 2
B8 3 0 3 1 0 2
B9 2 0 3 1 0 2
C1 3 0 3 1 1 2
C10 3 0 2 1 0 2
C11 3 0 3 1 0 2
C12 4 1 4 1 0 2
C13 4 1 3 1 0 2
C2 3 0 2 1 0 2
C3 3 0 3 1 0 2
C4 3 0 2 1 0 2
C5 3 0 3 1 0 2
C6 3 0 3 1 0 2
C7 3 0 3 1 0 2
C8 3 0 2 1 0 2
C9 3 0 3 1 0 2
ADMET: Absorption, distribution, metabolism, excretion and toxicity
of these compounds are reliable. Together, the results also provide 
evidence to show that the inhibitory effect of the azaindole derivatives 
against Aurora kinase, could aid in determining the lead molecules 
against cancer.
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